Dogwood Therapeutics, Inc. (DWTX) NASDAQ
2.11
-0.02(-0.94%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.11
-0.02(-0.94%)
Currency In USD
Address
44 Milton Avenue
Alpharetta, GA 30009
United States of America (the)
Phone
866 620 8655
Website
Sector
Healthcare
Industry
Biotechnology
Employees
12
First IPO Date
December 17, 2020
| Name | Title | Pay | Year Born |
| Gregory Duncan | Chairman & Chief Executive Officer | 842,082 | 1965 |
| William L. Pridgen | Founder & Member of Scientific Advisory Board | 16,333 | 1961 |
| Ralph D. Grosswald | Senior Vice President of Operations | 274,693 | 1969 |
| Angela Walsh | Chief Financial Officer, Secretary & Treasurer | 346,394 | 1967 |
| R. Michael Gendreau | Chief Medical Officer | 486,785 | 1956 |
| Carol Duffy | Chief Scientific Advisor | 0 | N/A |
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.